Clinical Trial Update: Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of birinapant and conatumumab in relapsed ovarian and related cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• Birinapant
• Conatumumab (conatumumab)

Snippet

Sponsor: TetraLogic Pharmaceuticals | Conditions: Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal Cancer | Phase 1 | Status: COMPLETED